

**Clinical trial results:****PHASE II TRIAL OF THE EFFECT OF GEMCITABINE WITH
INTRAVENOUS OMEGA 3 FISH OIL INFUSION IN PATIENTS WITH
UNRESECTABLE PANCREATIC ADENOCARCINOMA.****Summary**

EudraCT number	2009-009470-27
Trial protocol	GB
Global end of trial date	01 June 2014

Results information

Result version number	v1 (current)
This version publication date	22 March 2020
First version publication date	22 March 2020

Trial information**Trial identification**

Sponsor protocol code	Version 4 27/06/2011
-----------------------	----------------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01019382
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	University Hospitals of Leicester NHS Trust
Sponsor organisation address	Gwendolen Road, Leicester, United Kingdom, LE5 4PW
Public contact	Mrs Carolyn Maloney R&D department Leicester General Hospital Leicester LE5 4PW, University Hospitals of Leicester, +44116 2584109, carolyn.maloney@uhl-tr.nhs.uk
Scientific contact	Chris Mann Leicester General Hospital Gwendolen Road Leicester LE5 4PW , Department of Surgery , chris.mann@doctors.org.uk

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	06 August 2014
Is this the analysis of the primary completion data?	Yes
Primary completion date	01 June 2014
Global end of trial reached?	Yes
Global end of trial date	01 June 2014
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Objective response rate (complete + partial response) of response of patients receiving gemcitabine plus parenteral omega-3. To assess the effect of intravenous (given by a drip into the blood vessels) omega-3 fish oil, in combination with standard gemcitabine chemotherapy protocol upon patients with advanced pancreatic cancer.

Protection of trial subjects:

This study provides little potential risk over and above standard clinical care. The main ethical issue anticipated is the desire of patients to continue fish oils despite careful explanation of the lack of proven benefit. Since the side effect profile of taking oral fish oils is very safe, oral preparation will be offered to these patients. Otherwise this study is felt to be very safe and of potential benefit. Rare complications of study treatments aside, little harm can be expected to come to patients, and the potential benefits should be explored.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	23 November 2009
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 50
Worldwide total number of subjects	50
EEA total number of subjects	50

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0

Adolescents (12-17 years)	0
Adults (18-64 years)	15
From 65 to 84 years	35
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

50 patients will be recruited to the study. This number has been calculated to give the study sufficient power. There will be no control group as this is a phase IIa exploratory therapeutic trial. Results will be reviewed after 21 patients have been recruited. If two or fewer patients have a response of CT scan to treatment, the trial will be stop

Pre-assignment

Screening details:

Eligible patients (>18 years of age) had an ECOG performance status of 0 or 1, histologically proven locally advanced and or metastatic pancreatic adenocarcinoma, measurably disease on CT by RECIST 1.1 criteria and have not received prior chemotherapy. Patients could not have undergone any major surgical procedure within 4 weeks

Period 1

Period 1 title	Recruitment (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Arm 1
Arm description: A single arm trial	
Arm type	Experimental
Investigational medicinal product name	Lipidem
Investigational medicinal product code	PR 1
Other name	
Pharmaceutical forms	Emulsion for infusion
Routes of administration	Intravenous use

Dosage and administration details:

10 ml of lipidem 200mg/ml per kilogram body weight per day by intravenous infusion. Total dose per day 500 ml

Number of subjects in period 1	Arm 1
Started	50
Completed	35
Not completed	15
early death and withdrawal from treatment	15

Baseline characteristics

End points

End points reporting groups

Reporting group title	Arm 1
Reporting group description:	
A single arm trial	

Primary: objective response rate which is a percentage of patients experiencing a 30% or greater reduction in the size of their target lesion at any point subsequent to commencing on treatment on CT

End point title	objective response rate which is a percentage of patients experiencing a 30% or greater reduction in the size of their target lesion at any point subsequent to commencing on treatment on CT ^[1]
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

objective response rate which is a percentage of patients experiencing a 30% or greater reduction in the size of their target lesion at any point subsequent to commencing on treatment on CT (which is measured)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis title: simon's two stage design.

Description : This design was used so there is no formal statistical analysis for the primary outcome measure.

Type: optimal design p0 (0.10), and p1 (0.25) were parameters used for the design with rejection parameters of 2/21 patients for the first stage and 7/50 patients for the complete trial.

End point values	Arm 1			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: number of patients (0-50)				
number (not applicable)	50			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

This varies between patients. Assuming toleration of chemotherapy, the minimal amount of time each patient will be in the trial is 8 weeks. Patients will exit on disease progression and will continue until this occurs, or consent withdrawn

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	23.0

Reporting groups

Reporting group title	Arm 1
Reporting group description:	-

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: non-serious adverse events were not recorded for this study

Serious adverse events	Arm 1		
Total subjects affected by serious adverse events			
subjects affected / exposed	28 / 50 (56.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Vascular disorders			
Hypotension			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			
Elective ERCP & stent change			
subjects affected / exposed	5 / 50 (10.00%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
surgical gastro jejunostomy			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Pyrexia			

subjects affected / exposed	3 / 50 (6.00%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Hypothermia			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Elevated temperature			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
SOB unknown cause			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Investigations			
raised LFTs			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Tachycardia			
subjects affected / exposed	3 / 50 (6.00%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
ST elevated MI			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Vertigo			

subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 50 (4.00%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	2 / 50 (4.00%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infective enteritis			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Diarrhoea			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Cholangitis			
subjects affected / exposed	2 / 50 (4.00%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Biliary colic			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

obstructive jaundice			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Liver failure			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Biliary obstruction			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blocked biliary stent			
subjects affected / exposed	4 / 50 (8.00%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
External biliary drain			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Cellulitis			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Bilateral cellulitis			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
acute renal failure			
subjects affected / exposed	2 / 50 (4.00%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		

Deteriorating renal function subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 50 (2.00%) 0 / 1 0 / 0		
Endocrine disorders Newly diagnosed IDDM subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 50 (2.00%) 0 / 1 0 / 0		
Infections and infestations Empirical infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 50 (2.00%) 0 / 1 0 / 0		
Biliary sepsis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	3 / 50 (6.00%) 0 / 3 0 / 0		
Infected biliary stent subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 50 (2.00%) 0 / 1 0 / 0		
Sepsis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 50 (2.00%) 0 / 1 0 / 0		
Neutropenic sepsis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 50 (4.00%) 0 / 2 0 / 0		
Chest infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 50 (4.00%) 0 / 2 0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Arm 1		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 50 (0.00%)		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
01 June 2010	Protocol Variation and Lipidem Dose Reduction The dose of IV ω -3 could be reduced in the interest of patient safety at the discretion of the investigator should any adverse events occur thought to be attributable to the infusion. The infusion would be discontinued and subsequent treatments given at a 25% or 50% dose reduction. Dose reductions below 50% were not allowed.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported